newsfilter
← Latest News
Earnings Call Transcripts·

Vaxcyte Inc - 1781026 - VAXCYTE INC

Good afternoon. My name is Aiden Bracken. I'm a director on the UBS Biotechnology Investment Banking Team. Thank you all for attending on our second day of our inaugural UBS biopharmaceutical conference here at the Rosewood Hotel. And with that, I am happy to introduce Benjamin Oaks, the co-founder, president and CEO of Scribe Therapeutics. Benjamin. Thank you. All right. So there's like three of you here, which is fantastic. So what I will say is, if you have questions during this, please let me know. I'm going to just stare at you the whole time and engage directly with you, make you really uncomfortable. No, it's a pleasure to be here. Thank you, Aiden, for inviting us to give a talk. We're excited to continue to kind of get our story out there. Scribe went public about three months ago, but we've been operating as an organization for over eight years now. And Scribe is really predicated on my background with about 15 years of molecular engineering expertise. So that expertise is one that has been focused on genome editing and genetic modification proteins for a very long time. I started out working on zinc-fungal nucleases back when they were the only game in town for those who remember those. And then I joined Jennifer's lab once she put me out of business with CRISPR molecules. So we've been working on CRISPR molecule since 2013. And as an organization, we've built something that is actually quite a bit different. We're highly disciplined, very focused, and we execute, I think, with a lot less capital than almost every one of our peers in this space. And that has been really valuable for us to advance a number of programs. Before I get into that, though, I do want to reiterate that our whole focus has been to build, essentially, CRISPR technology, take CRISPR technology to the next level. And what we mean by that is actually making it safe and effective enough to be used by all of us. So since there's only three of us in this room, the statistics dictate that there's at least one of us who is going to be suffering from ASCVD, likely actually two of us. And given the ages I'm seeing, actually probably the two males here already have plaque in their arteries. I know I do. And actually, these are new stats. These are new states that have just come out of AHA and ESC suggesting that 50% of males between the age of 30 and 50 essentially already have plac. this makes this the leading cause of disease and morbidity and mortality globally and because we can address lipids with CRISPR technologies if we can make them safe and effective enough it gives us the ability to essentially prevents potentially the leading causes of death globally the way we are doing this is with custom engineered CRISPR Technologies that start out on the lower left hand corner here with an entirely novel molecule called CasX so CasX is less than 5% identical to Cas9. That gives us the ability to essentially build our own platform. But that molecule starts out not working super well. Actually, it barely edits the human genome. And I can now say, actually, up on BioRxiv is a paper we have just published, basically showing about five years of work taking that molecule and turning it into something that we call the X-Editor. The X- Editor is a highly evolved molecule for potency and specificity. In that paper, we show that we have essentially moved over 120 steps through sequence space to a much more potent and specific, and therefore potentially safe molecule that enables us to do highly effective genome editing. But genome editing is just one approach we can use to modify disease. And we wanted to try to figure out how we could bring genetic medicine technologies really to the broadest groups possible. And that is where we built this epigenetic silencing technology we call the epigenatic long-term ex-repressor. The epigenetic long-term exopressor or the elixir is a molecule that allows us to target a specific location in the genome, but without causing any DNA damage whatsoever, we can actually turn off that target gene. And we really like this because what we think it will allow us to do is unlock essentially the transfer of protective genetics in a safe and effective way. So for example, about 1% of the patient population has a gene or a genetic mutation that's likely to prevent you from ever having a heart attack. Maybe that's a little bit of an overstatement. It's about 80 to 90 percent. The question is, can we give everyone access to genetics that looks like that? And that is what the Elixir technology is focused on doing. So we are applying that technology, the Eluxir epigenetic silencer, to LDL-C lowering first. This is the PCSK9 mutation that is very well understood and, again, can lower ASCVD by over 80 percent. That molecule is in the clinic in phase one. We are anticipating data in the first half of next year, so that is going to be a large inflection point for us. The second and the third programs are for LP little a lowering and triglyceride lowering, and those are using the genome editing approaches. Specifically, they are moving forward in parallel with support of the California Institute for Genetic Medicine. Those two approaches are focused on the genetic diseases that underpin those dyslipidemias, You know, highly elevated LPAA and highly elevated triglycerides. The first one of those programs will enter the clinic next year with the second program likely entering the clinic the year after that. The IPO that we just did does actually fund all three programs to a phase one initial proof of concept data. That's our goal. So in addition to that, because we have built our platforms from scratch, we do also have the ability to do work outside of cardiovascular metabolic disease. But as I mentioned at the top, we are a very focused organization, and that means when we're doing work outside of CVM, we are really focused on finding partners to do it with. Right now, we're working actively with Sanofi in in vivo sickle cell and a number of other genetic medicines that we haven't yet disclosed. And this has been a highly productive collaboration that's been going on for about four years now. We actually just announced an expansion of this to use the epigenetic silencing technology. We also are working with Lilly in vivo in neurological and neuromuscular diseases. And actually, both Sanofi and Lilly did invest in the IPO recently. And then finally, as I previously mentioned, we have grant funding from the California Institute for Adrenaline Medicine to fund both that 1200 and 1400 program and push that forward, which we're very excited about doing because it does significantly offset the burn. So let's jump into the data now. The lead program, again, is the Epigenetics Counselor for LDLC. I think the interesting thing about LDL-C lowering is that if you look at the space we all know and are aware and maybe some of us are even on small molecules or antibodies that lower LDL C there are a number of very good drugs in this class that you can lower if you combine them LDLC by as much as 90 percent so the the natural question is wait why are you building another LDL c lowering medicine? And the answer is, while these drugs work very well clinically, in the real world is where we actually see the issue. And this makes perfect sense because, again, if these drugs were good enough, ASCVD wouldn't be the leading cause of disease or death and disease globally. Right now, small molecules lose 70% of patients within the first year. This is a drug you need to be on for over a decade, most likely decades. We can't keep a majority of patients on medicine for even one year. Antibody is 50%. And RNAi, the RNAi therapies for PCS canine are very new. But what we have seen is that within the first year, about 20% of patients can't come back for their first redose. So even longer acting therapies, like every six months, aren't going to solve this problem. And this is not just an American problem. Actually, the study I'm showing you here on the right-hand side actually comes directly from real-world data out of Germany. And the stats are basically identical. It's really astonishing just how poorly patients are adherence to these drugs. So what is our goal? Our goal is to make a drug that can solve for essentially human behavior and recapitulate these known protective genetics by creating this ultra-long-acting PCSK9 silencing drug, right? The way to think about this is, that one's open already. The way to think about this is essentially, imagine if you can make an RNAi medicine that lasted for years to decades rather than weeks to months. And what I'll show you is that we are achieving this already in non-human primates. It looks very tolerable, and we have data in actually less than six months. So really quick, how does epigenetic silencing work? Let's start out upstream of the gene PCSK9. We all have something what's known as open chromatin. This is permissive of mRNA transcription. Essentially, we can produce a lot of mRNA from this. What we can do is deliver via lipid nanoparticle, mRNA and guide RNA, a molecule that translates into the elixir and is targeted to that upstream portion right in front of PCSK9. That writes marks on chromatin, essentially histone tails, as well as DNA CPG methylation. Those two marks are read by the cell. Chromatin is compacted, and what you get is essentially a non-permissive state for PCSk9 transcription. We are lowering PCSK9 in a very similar way to RNAi, just lowering the amount of PCSk9 mRNA, but rather than degrading hundreds or thousands of mRNA molecules every day, we're just asking the cell not to produce it in the first place. And the proof is in the pudding. Here's what you can see in non-human primates. We deliver these molecules at day zero, and it is very clear that they are essentially gone by day seven. but the effect we're able to have with the epigenetic silencer lasts through 720 days, or roughly two years, without any sign of degradation. We are getting greater than 50% LDL-C lowering at all doses, and at that lowest dose, the therapeutically relevant dose of 0.75 mg per kg, we do not see any sign OF epigenet reactivation. We see that both from an LDL C perspective, when we actually ended the study and took these monkeys down, and we look in the the epigenome, what we see is there's no sign from a molecular perspective in terms of loss of CPG methylation either. The last thing I'll note here is the non-human primate genome essentially turns over every 200 to 250 days. So these marks are being faithfully passed, recapitulated from mother cell to daughter cell multiple times now, at least three times in this study. So this gives us a lot of excitement and trust that this is going to be a therapy that last multiple years, if not potentially decades. The next thing we can do is, okay, well, if it lasts a decade, let's say, you will want to go back in and redose. So it'll look kind of like a Tdap booster, right? Can you redose? And what we've shown in non-human primates is that as close together, actually as 42 days apart, you can redose, and actually in this instance, what we're showing is you can actually even titrate in further LDL-C lowering if you want to. So the ability to redose is possible without any reduction in tolerability. What I'm showing you down here is ALT, but ALT AST and bilirubinol look completely identical to a saline or saltwater infusion. That's the open circles there. The next question is of course, tolerability, it is a CRISPR based genetic medicine. So we do want to ensure on target versus off target specificity. This is something that is, um, we, we are, we're some, an area where we are held to a much higher bar than, for example, ASOs or RNAi. I actually have to show you we're not hitting other genes. And what we can do is a lot of engineering to ensure that our molecules are specific enough. On the left-hand side, I'm showing you essentially whole transcriptome differential regulation of essentially mRNA. And you can see this is a volcano plot. If genes were being differentially regulated, you would see kind of a splash of different genes. The only gene that's differentially related is PCSK9 up here. I'm just going to stand here now. It's much easier for me to point you need like a laser pointer um so this leaves us with this other side of the potential tox uh species that is lmp related tox we've seen lmp-related tox in the genetic medicine space now in a couple different instances and what we find working with our partners at acuitas with um after you know closely selecting and optimizing our lipid formulations that again below one mg per kg we are indistinguishable from a saltwater infusion which is those open circles the last piece of i think really interesting information here is the translatability information so everything i just showed you in the non-human primate genome is of course on the nonhuman primates genome we designed this drug to work on the human genome when instead we take the human gene we put it in a transgenic mouse model with the upstream and downstream epigenetic components what we see is that our potency per unit dose substantially increases We are fully saturating somewhere around 0.6 mg per kg. It's about twofold more potent than what we saw in the non-human primate. Same thing happens in primary human hepatocytes, comparing them to primary syno-hepatocytes. In this instance, it's about five to eightfold more potent. I would say directionally, it is in the correct direction, but it is obviously significantly more. I Would take that with a grain of salt because it is an in vitro assay. So that leaves us, I think, with a really attractive drug kind of in the clinic right now, dosing in patients. And to think about where we're aiming to get to next year, I want to lay out the TPP based on what we have available. Right now, if you have statins, you have antibodies like Repatha and Prolulent, or you have Inclisirin, you have Lectio in this space, all of these drugs can achieve somewhere between 40% and 60% LDL-C lowering clinically. Not a single one of them keeps all patients on drug. So if you actually do the essentially adherence-adjusted or persistence-adrasted modification, your LDL-C lowering over the course of one year for your patients roughs out to about 15% to 23% with the small molecules or the statins, excuse me, small molecules of the antibodies, and about 35% with RNAi. That means if we can create a drug that achieves greater than 35% lowering, we already have 50% in non-human primates and as high as 68%, and keeps all patients on drug for just one year, when we have two years of data we will have created essentially a best-in-class molecule the thing that's even more exciting is that 35 is the bar but again we've already shown and we know potentially we should be able to get much higher than that the the last piece of information i'll give you if you guys recall the pcs can i mutations is that pcs mutations that are known to lower ldlc only lower ldc by about 30 and still reduce cardiovascular risk by 50 to 80 if you can get lifelong, essentially LDL-C lowering. And so that really is the bar we're trying to hit, greater than 30%, greater than 35%. But we think we may be able to get much higher than that. So we are in the clinic, we are actively enrolling patients and dosing patients in Australia. The interesting thing about our clinical trial right now is that we also, in discussions with regulators, have been able to actually bring this therapy, because it is an epigenetic silencer, to a broader set of patients than almost all the genetic medicine therapies before us. If you look at the base editing therapies or the genome editing therapies, they have really had to be focused on rare genetic disease subsets of dyslipidemia. We have actually been able to open this trial with a study population of adult patients with elevated LDL-C and elevated risk. And that is something we're excited about continuing forward. We really think about the epigenetics silencing therapy as being the umbrella for all patients with lipid risk and potentially being able to offer this very broadly and widely. So the last thing I'll say on the value return or the commercial side of the LDL-C drug, and I know this is an incredibly busy slide, so bear with me, but essentially across all of your different parties who have a say in this, every single one has a lot to gain. And for the first time, there may be an opportunity to actually return value to the system in a way where because of the COGS here, because of the market, because 1% of patients being on PCSK9 inhibitors today is yielding about $5 billion, we have the ability to treat the remaining 99%, essentially, who are not yet on this drug or transition the 1% who are on and really have a competitive pricing discussion with many folks. That, we think, is really interesting because it will have the potential opportunity, again, to change how the system's currently functioning. So with that, I'm going to touch very quickly on the second, third program and the third program. Again, both of these now are with the genome editor because these are genetic dyslipidemias. The first thing I'll mention is, again we just published a paper on how we have engineered and evolved CasX into something we call the X-editor. It is over 125 steps through sequence space. It is, to our knowledge, the best or the most potent molecule. And we've demonstrated this in multiple non-human primate studies now, while also at the same time demonstrating that even at 10x supersaturation doses, we don't see off-targets. So off- target risk is one of the primary risks you would associate with genome editing. And the question becomes, if you don't have off-target risk. How does the world potentially look different? Do we start to think about genetic medicines in a different way? So jumping next to LP little a, I think there's, I don't know if anyone here is familiar with LP little A or the recent horizon studies that have kind of had some misses here, but it is an incredibly well-validated genetic risk for elevated or for elevating cardiovascular disease. However, it does appear that actually short-term pharmacological intervention in LP little a at the end of life, isn't going to move the needle. It really appears like you're going to have to be treating LP little A for a much larger portion of a patient's lifetime. And because of that, we think that genome editing is perhaps one of the only, if not the only way to actually approach this disease. In short, we are able to build highly potent genome editors that are fully saturating at around 0.2 mg per kg in a humanized LpA mice. This is reducing the target gene by over 90% to 95%. When we actually look at all of the potential off-targets here, over 125 different, quote-unquote, at-risk sites, we don't see any off-target editing. If you're familiar with LpLA, you know that it's homologous to plasminogen. We see no change in plasmonogen either. And then finally, when we move this to non-human primates, we can get really potent editing and reduce LPA, again, by greater than 95%. So there's this really interesting opportunity now to essentially recapitulate the genetics of low LPA in patients who are born with very high LPA. Last is triglycerides. So extremely elevated triglyCERIDES also pose significantly elevated rates of cardiovascular risk. on top of that what we've seen recently is that they also modify and actually potentially cause acute pancreatitis in very meaningful ways um the the folks who are most at risk of this are in the fcs and mcs categories this is either genetically defined or clinically defined as triglycerides greater than 880 and what we think we can do is provide the patients now who are actually just about to be getting access to ASOs and RNAi-style approaches from Arrowhead and Nyonis in this category, in about five years, give or take, the opportunity to have a curative approach and be able to transition these patients from the therapies that currently exist to therapies that may better suit the lifetime of treatment they need. So again, in the FCS or a hypertriglyceridemic mouse model, we're able to reduce ApoC3 by greater than 96%. This is an extremely elevated mouse, so these numbers are very elevated as well. Triglysterides by greater Than 95% and total cholesterol by 80%. This is really striking. This is the only time I've been able to actually observe genome editing. So if you look all the way on the right-hand side here, you can see the mouse, these mice are essentially pumping candle wax. So there's so much lipid in their blood. And you can return that to phenotypically normal serum. Again, from an off-target perspective, we don't see off-target risk here. 10x supersaturation doses in primary human hepatocyte donors, multiple of them. We haven't seen off-arget editing with our lead guide, so we're really excited about this. And so to wrap up, again, in non-human primates, 0.5, 1 mg per kg, 2 mg perkg, we're fully saturating by 1 mg prokg. We're likely saturating somewhere between 0. 5 and 1 mg prekg in terms of lipid dose. Again, below 1 mg por kg, essentially from a tolerability perspective, we are indistinguishable from that salt water infusion which is something that we're excited about so to wrap up this is what our goal is right our goal is to take medicine as it exists today this late symptomatic intervention paradigm and potentially provide us all with the opportunity to get treated early take those cardioprotective genetics and give them to everybody and extend health span potentially extend lifespan. And this is something that is quite near and dear to my heart. Many of these drugs are drugs that I think will be impactful for myself and my family. And right now we are, as I mentioned, in the clinic. So we initiated that trial the middle of this year, right about the time we went public. Data will be in the first half of next year. LPA and triglycerides are moving forward together right now. We will choose one to advance next year, and then, of course, we'll have additional updates. So with that, we do have a little bit of time. If there are questions, there's so few of you, I can just take them. Yeah. This is Ash from UBS. I mean, we saw the detailed Pelle Carson data and a lot of data cuts within that, subgroup analysis and everything. So I guess you're saying that more than 95% reduction can now make a difference? It's not the amount of reduction. I think the really interesting data that comes out of Verizon is how negative it is, right? Just how negative is. I think what we misconstrued based on our understanding of LDLC is the fact that you could treat LDLC late in life and actually take a large portion of your total LDLC exposure out, right? So if you look at LDLC, LDLC in men rises over time, starts to precipitously rise past the age of 30, really past the edge of 40, and then kind of flattens out around the age of 50 or 60. So if we look at the age of 50, so if you treat someone at 50 or 50, you're taking a huge chunk of their future LDLC exposures out. Lp little a is the exact opposite. Lp is like very high and just stays high. goes flat. If you treat someone at the age of 60, which was the average age of the study, by the way, the most severe LPA patients have already had all their events, and this was a secondary event study. You're taking a very small sliver out. And so all of the discussions we've had with KOLs have actually moved to getting much more and more excited about preventative medicine for LpA. The primary prevention studies that are actually going on right now are where people are really turning their eye to. I don't know if we really think Ocean is going to move the needle right now for Lp little a, but it remains to be seen. They may be able to adjust that trial to be a little bit smarter about it. Yeah. And if we go back to the previous slide, just in terms of choosing between these two programs, the LPA or triglyceride. Yeah, I mean, what, like, in your mind, what is the sort of the standard of care for triglyceral right now what's the effective uh bar that uh yeah so triglyceride lowering right now um i'm gonna i'm going to mess up the names of the drugs so i'm not gonna even try them but ionis is drug and arrowhead's that drug yeah yeah um both of those are either approved or headed to approval depending on the jurisdiction and what we're looking at is somewhere between really 60 and 80 percent triglyceral lowering based on apoc3 knockdown right the interesting thing is the again these are drugs have to be delivered every month to every three months in these patients and we think that there will be an opportunity especially as these patients see okay i'm on this drug it's working for me it's preventing my acute pancreatitis flare-ups which were likely happening pretty recent pretty um many times per year most of these patients um we can offer them essentially the one and done solution for, you know, essentially transitioning them from the once a month to a highly durable approach when you already know that drug works for you, we think is actually a really interesting opportunity. Thank you.

Company
VAXCYTE INC
Keywords
VAXCYTE INC